Tysabri Progressive Multifocal Leukoencephalopathy Settlement: Statute of Limitations for Tysabri in Ohio

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Education to Specific Risk Awareness

The legacy of mass production in the health information domain has long centered on disseminating general wellness guidance and broad scientific literacy, serving as a foundation for public understanding of medical risks. This heritage established a framework for communicating complex health data to diverse audiences, emphasizing clarity and accessibility. Within this tradition, the focus now shifts to a specific, high-stakes area: the occupational and patient exposure to therapeutic agents with known serious side effects. In particular, the transition from general health education to the nuanced risk of Progressive Multifocal Leukoencephalopathy (PML) associated with Tysabri (natalizumab) represents a critical pivot. This medication, used in the management of certain autoimmune conditions, carries a documented risk of PML, a rare but severe brain infection. For individuals in Ohio who have been prescribed Tysabri and subsequently developed PML, understanding the legal and temporal boundaries for seeking recourse becomes paramount. The statute of limitations for filing a Tysabri-related PML settlement claim in Ohio is a finite window that begins from the date of diagnosis or when the injury was reasonably discoverable. This transition from general health information to a focused legal and medical concern underscores the need for precise, actionable knowledge regarding exposure risk and the time-sensitive nature of legal remedies.

Find Out If You Qualify for Compensation →

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for moderate-to-severe active Crohn's disease in adults who have had an inadequate response to or cannot tolerate conventional therapies (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). A central and serious risk associated with Tysabri is progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The prescribing information for Tysabri includes a boxed warning stating that the drug increases the risk of PML and that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML, with dosing withheld immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three established risk factors for developing PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against expected benefit when initiating and continuing therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which requires patients to read a Medication Guide, understand the risks, and sign a Patient Enrollment Form; pharmacies and infusion centers must also be specially certified (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation and Mechanism of PML

The clinical presentation of PML can include progressive neurological deficits such as weakness, cognitive changes, visual disturbances, and coordination problems. Diagnosis typically involves brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via PCR. The mechanistic pathway linking Tysabri to PML involves the drug's inhibition of alpha-4 integrin, which prevents lymphocyte trafficking into the central nervous system. This reduced immune surveillance allows latent JCV to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and neuronal damage. The timeline between Tysabri exposure and documented PML harm can vary, with cases reported after a few months to several years of treatment, though risk increases with longer duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Legal Considerations and Statute of Limitations in Ohio

For patients in Ohio who have developed PML after Tysabri use, settlement-related considerations involve evaluating the adequacy of warnings provided by the manufacturer. The boxed warning and prescribing information clearly state the PML risk and the need for monitoring, but questions may arise about whether these warnings were sufficiently communicated to patients and healthcare providers before and during treatment. The TOUCH program is designed to ensure risk awareness, but its implementation and the timing of risk disclosure could be relevant in legal contexts. Affected patients or their families may seek compensation for medical expenses, lost income, pain and suffering, and other damages. The statute of limitations for filing a Tysabri-related PML lawsuit in Ohio is generally governed by state product liability and personal injury laws, which typically require claims to be brought within a certain number of years from the date of injury or from when the injury was discovered or should have been discovered. Given the serious and often delayed nature of PML, the discovery rule may apply, meaning the clock starts when the patient knew or reasonably should have known that Tysabri caused the harm. It is essential for affected individuals to consult with a qualified attorney promptly to understand the specific deadlines that apply to their case, as failure to file within the statutory period can bar recovery. In summary, Tysabri carries a well-documented risk of PML, with identifiable risk factors and a mechanistic basis involving immune modulation. The manufacturer has provided warnings through labeling and a restricted distribution program, but the adequacy of these warnings in individual cases may be subject to legal scrutiny. For Ohio patients harmed by PML, settlement considerations include the timing of diagnosis, the presence of risk factors, and the applicable statute of limitations, which requires timely legal action.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in Ohio?

The statute of limitations for Tysabri-related PML claims in Ohio is governed by state product liability and personal injury laws. Typically, claims must be filed within a certain number of years from the date of injury or from when the injury was discovered or should have been discovered. Because PML can have a delayed onset, the discovery rule may apply, meaning the clock starts when the patient knew or reasonably should have known that Tysabri caused the harm. It is crucial to consult an attorney promptly to determine the specific deadline for your case.

What are the risk factors for developing PML from Tysabri?

Three established risk factors for developing PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against expected benefit when initiating and continuing therapy.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.